Neurological disease: UPS stops delivering!

Trends in Pharmacological Sciences

Volumn 24, Issue 1, 2003, Pages 18-23

  Miller, Richard J ^a   Wilson, Scott M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; MUTANT PROTEIN;

APOPTOSIS; CELL ACTIVITY; CELL CYCLE; MOLECULE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; REVIEW;

EID: 0037215674     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)00011-1     Document Type: Article

References (52)

1. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67:1998;425-479.
2. Wojcik C. Ubiquitin - more than just a signal for protein degradation. Trends Cell Biol. 11:2001;397-399.
3. Bedford F.K., et al. GABA-A receptor cell surface number and subunit stability are regulated by the ubiquitin like protein Plic-1. Nat. Neurosci. 4:2001;908-916.
4. Kretz-Remy C., Tanguay R.M. SUMO/sentrin; protein modifiers regulating important cellular functions. Biochem. Cell Biol. 77:1999;299-309.
5. Tran P.B., Miller R.J. Aggregates in neurodegenerative disease: crowds and power. Trends Neurosci. 22:1999;194-197.
6. Alves-Rodrigues A., et al. Ubiquitin, cellular inclusions, and their role in neurodegeneration. Trends Neurosci. 21:1998;516-520.
7. Bence N.F., et al. Impairment of the ubiquitin proteasome system by protein aggregation. Science. 292:2001;1552-1555.
8. Jensenberger V., Jentsch S. Deadly encounter. Ubiquitin meets apoptosis. Nat. Rev. Mol. Cell Biol. 3:2002;112-121.
9. Van Leeuwen F.W., et al. Frameshift mutations of β-amyloid precursor protein and ubiquitin b in Alzheimer's and Down's patients. Science. 279:1998;242-247.
10. Lam Y.A. Inhibition of the ubiquitin proteasome system in Alzheimer's disease. Proc. Natl Acad. Sci. USA. 97:2000;9902-9906.
11. De Vrij F.M., et al. Mutant ubiquitin expressed in Alzheimer's disease causes neuronal death. FASEB J. 15:2001;2680-2688.
12. Lindstein K., et al. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J. Cell Biol. 157:2002;417-427.
13. Keller J.N., et al. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75:2000;436-439.
14. Kim T.W., et al. Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J. Biol. Chem. 272:1997;11006-11010.
15. Sherman M.Y., Goldberg A.L. Cellular defense against degraded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.
16. Lin X. Expanding our understanding of polyglutamine diseases through mouse models. Neuron. 24:1999;499-502.
17. Zoghbi H.Y., Orr H.T. Glutamate repeats and neurodegeneration. Annu. Rev. Neurosci. 23:2000;217-247.
18. Mitchell I.J., et al. The selective vulnerability of striatopallidal neurons. Prog. Neurobiol. 59:1999;691-719.
19. Cummings C.J., et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine induced pathology in SCA1 mice. Neuron. 24:1999;879-892.
20. Jana H.R., et al. Expression of A53T mutant but not wild type alpha synuclein in PC12 cells induces alterations of the ubiquitin dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21:2001;9459-9460.
21. Albrecht U., et al. Imprinted expression of murine Angelman syndrome gene, Ube3a, in hippocampal and purkinje neurons. Nat. Genet. 17:1997;75-78.
22. Jiang Y.H., et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic and defecits of contextual learning and long term potentiation. Neuron. 21:1998;799-811.
23. Saudou F., et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of nuclear inclusions. Cell. 95:1998;55-66.
24. Watase K., et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron. 34:2002;905-919.
25. Fernandez-Funez P., et al. Identification of genes that modify ataxin-1 induced neurodegeneration. Nature. 408:2000;101-106.
26. Glasson B.I., Lee V.M.Y. Parkin and the molecular pathways of Parkinson's disease. Neuron. 31:2001;885-888.
27. Spillantini M.G., et al. Alpha synuclein in Lewy bodies. Nature. 388:1997;839-840.
28. Clayton D.F., George J.M. The synucleins; a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21:1998;249-254.
29. Polymeropoulos M.H., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
30. Jha N., et al. Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway; relevance for Parkinsons disease. J. Neurochem. 80:2002;555-561.
31. Ostrerova-Golts N., et al. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20:2000;6048-6064.
32. Paxinou E., et al. Induction of α-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21:2001;8053-8061.
33. Lee H.J., et al. Formation and removal of α-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277:2002;5411-5417.
34. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:1998;605-608.
35. Shimura H., et al. Ubiquitination of a new form of α-synuclein by parkin from human brain; implications for Parkinson's disease. Science. 293:2001;263-269.
36. Chung K.K.K., et al. Parkin ubiquitinates the α-synuclein-interacting protein, synphilin-1: implications for Lewy body formation in Parkinson's disease. Nat. Med. 7:2001;1144-1150.
37. Imai Y., et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell. 105:2001;891-902.
38. Schlossmacher M.G., et al. Parkin localizes to the Lewy bodies of Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 160:2002;1655-1667.
39. Tanaka Y., et al. Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria dependent apoptosis. Hum. Mol. Genet. 10:2001;919-926.
40. Ghee M., et al. Rat α-synuclein interacts with rat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem. 75:2000;2221-2224.
41. Stefanis L., et al. Expression of A53T mutant but not wild type α-synuclein in PC12 cells induces alterations of the ubiquitin dependent degradation system in Parkinson's disease. Nat. Rev. Neurosci. 2:2001;589-594.
42. McNaught K.S., et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2:2001;589-594.
43. Leroy E., et al. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
44. Satoh J., Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C terminal hydrolase 1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci. 189:2001;113-117.
45. Saigoh K., et al. Intragenic deletion in the gene encoding ubiquitin carboxy terminal hydrolase in gad mice. Nat. Genet. 23:1999;47-51.
46. Kurihara L.J., et al. Loss of UCH-L1 and UCH-L3 leads to neurodegeneration, posterior paralysis and dysphagia. Hum. Mol. Genet. 10:2001;1963-1970.
47. Miller R.J. Calcium channels prove to be a real headache. Trends Neurosci. 20:1997;189-192.
48. DiAntonio A., et al. Ubiquitination dependent mechanisms regulated synaptic growth and function. Nature. 412:2001;449-452.
49. Fischer J.A., Overstreet E. Fat facets does a highwire act at the synapse. BioEssays. 24:2002;13-16.
50. Wilson S.M., et al. Synaptic defects in ataxia mice result from a mutation in USP14 a ubiquitin specific protease. Nat. Genet. 32:2002;420-425.
51. Van Leeuwen F., et al. Proteins and aging. Int. J. Biochem. Cell. Biol. 34:2002;1502.
52. Ross C.A. Polyglutamine pathogenesis; emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron. 35:2002;819-822.